These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Vical initiates vaccine trials against HSV-2 and CMV. Riedmann EM Hum Vaccin Immunother; 2014; 10(2):255. PubMed ID: 24963522 [No Abstract] [Full Text] [Related]
5. A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy. Mo A; Musselli C; Chen H; Pappas J; Leclair K; Liu A; Chicz RM; Truneh A; Monks S; Levey DL; Srivastava PK Vaccine; 2011 Nov; 29(47):8530-41. PubMed ID: 21767588 [TBL] [Abstract][Full Text] [Related]
6. Potential for immunotherapy in the treatment of herpesvirus infections. Bernstein DI Herpes; 2001 Mar; 8(1):8-11. PubMed ID: 11867010 [TBL] [Abstract][Full Text] [Related]
8. Development of a therapeutic vaccine for HSV-2. Hosken NA Vaccine; 2005 Mar; 23(17-18):2395-8. PubMed ID: 15755634 [TBL] [Abstract][Full Text] [Related]
9. Shingles vaccine: who should get it? Johnson AM S D Med; 2006 Aug; 59(8):349-50. PubMed ID: 16941852 [No Abstract] [Full Text] [Related]
10. Construction, characterization and immunogenicity of a glycoprotein E negative bovine herpesvirus-1.1 Egyptian strain "Abu-Hammad". El-Kholy AA; Rady DI; Abdou ER; Elseafy MM; Abdelrahman KA; Soliman H J Virol Methods; 2013 Dec; 194(1-2):74-81. PubMed ID: 23962750 [TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive persons. Wald A; Koelle DM; Fife K; Warren T; Leclair K; Chicz RM; Monks S; Levey DL; Musselli C; Srivastava PK Vaccine; 2011 Nov; 29(47):8520-9. PubMed ID: 21945262 [TBL] [Abstract][Full Text] [Related]
12. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines. Alving CR; Rao M; Steers NJ; Matyas GR; Mayorov AV Expert Rev Vaccines; 2012 Jun; 11(6):733-44. PubMed ID: 22873129 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886 [TBL] [Abstract][Full Text] [Related]
15. Vaccine helps thwart herpes in women. AIDS Read; 2000 Oct; 10(10):574. PubMed ID: 11068791 [No Abstract] [Full Text] [Related]
16. Herpes zoster vaccine (Zostavax). Med Lett Drugs Ther; 2006 Sep; 48(1243):73-4. PubMed ID: 16977285 [TBL] [Abstract][Full Text] [Related]
17. Herpes simplex virus type 2 vaccines: new ground for optimism? Aurelian L Clin Diagn Lab Immunol; 2004 May; 11(3):437-45. PubMed ID: 15138167 [TBL] [Abstract][Full Text] [Related]
18. Meta-analysis of pregnancy outcomes in pooled randomized trials on a prophylactic adjuvanted glycoprotein D subunit herpes simplex virus vaccine. Tavares F; Cheuvart B; Heineman T; Arellano F; Dubin G Vaccine; 2013 Mar; 31(13):1759-64. PubMed ID: 23313657 [TBL] [Abstract][Full Text] [Related]
19. Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Wu JJ; Huang DB; Tyring SK Antiviral Res; 2004 Nov; 64(2):79-83. PubMed ID: 15498602 [TBL] [Abstract][Full Text] [Related]
20. Recombinant MVA expressing secreted glycoprotein D of BoHV-1 induces systemic and mucosal immunity in animal models. Ferrer MF; Del Médico Zajac MP; Zanetti FA; Valera AR; Zabal O; Calamante G Viral Immunol; 2011 Aug; 24(4):331-9. PubMed ID: 21830904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]